Procter & Gamble Health Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Procter & Gamble Health Ltd trades at ₹6,605, in a confirmed uptrend and 7 weeks into that stage. That is +14.0% against its own 200-day average. It sits at 88% of a 52-week range of ₹4,849 to ₹6,839. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 19 straight weeks.

Today the stock is in a confirmed uptrend — week 7 of stage 2, confirmed. At ₹6,605 it trades +14.0% versus its 200-day average and sits at 88% of its 52-week range (₹4,849–₹6,839).

Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved +905% while the NIFTY 500 moved +276% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 19 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Procter & Gamble Health Ltd trades at 33.5× P/E, mid-range by its own standards (39th percentile). Its long-run median P/E is 35.1×, measured across 10.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 33.5× is mid-range by its own standards (39th percentile), against a long-run median of 35.1× measured over 10.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

Why the multiple sits where it does: over the past year annual EPS moved +39.5% against a +6.2% price move — earnings outran the price, pushing the multiple DOWN its own range.

The price move, decomposed: over 5y, of the +4.3%/yr price move, ~+11.3%/yr came from earnings growth and ~−7.0 pp from the multiple (compressing); over 10y, of the +25.1%/yr price move, ~+18.9%/yr came from earnings growth and ~+6.2 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.

Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Procter & Gamble Health Ltd reads as mixed on its fundamental arc. Mixed — growth is normalizing off a hyper-growth base: profit growth has eased from +40.8% at its peak to +30.7% but is still expanding, ROCE lifting at 77.3%. The read is built from 12 quarters across 4 curves, on full evidence.

Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.

4-Factor Sector Score

75.3/100 — rank 1 of 8 in Pharma - MNC bulk Drugs · 90% evidence confidence

Procter & Gamble Health Ltd scores 75.3 out of 100 against the 8 companies it is compared with in Pharma - MNC bulk Drugs, ranking 1. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 28.7 + 21.2 + 14.6 + 10.8 = 75.3. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Procter & Gamble Health Ltd reported ₹370 Cr of revenue in the Mar 26 quarter, +19.0% year on year. That is the 5th straight quarter of year-on-year growth. Over 10 years it has compounded at 3.6% a year. The last full year, Mar 26, came in at ₹1,408 Cr. The last four reported quarters add to ₹1,408 Cr.

Mar 26 revenue came in at ₹1,408 Cr (+50.7% on the year), capping 10 years at 3.6% compound. The latest quarter (Mar 26) printed ₹370 Cr, +19.0% year on year — the 5th consecutive quarter of year-over-year growth.

Pace check: the last four quarters averaged +15.7% growth against the decade's 3.6% — the current year is running faster than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +15.6% over the last 4 quarters against +9.8%/yr over the last 8 — accelerating; TTM profit +30.7% vs +23.5%/yr — accelerating.

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Procter & Gamble Health Ltd's operating margin is 37.0% in the Mar 26 quarter, +11.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 7.0% to 34.0%. The current quarter is running above every full year in that window.

The latest quarter's operating margin is 37.0%, +11.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 7.0%–34.0%.

Why the margin moved: operating margin went +10.6 pp year on year while gross margin went +6.7 pp — the gain came mostly from the gross line: input costs and pricing.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Procter & Gamble Health Ltd earned ₹95.0 Cr of net profit in the Mar 26 quarter, +55.7% year on year. Full-year Mar 26 profit was ₹327 Cr. The 10-year compound rate is 15.3%. That is 25.7% of the quarter's revenue. The same quarter a year earlier earned ₹61.0 Cr.

Mar 26 profit was ₹95.0 Cr, +55.7% year on year. On the full year, Mar 26 printed ₹327 Cr (+39.7%), and the 10-year compound rate is 15.3%.

Why profit moved: revenue contributed +19.0% and the margin +11.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.

Pace comparison, last four quarters: profit +84.5% vs revenue +15.7%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 96% of Procter & Gamble Health Ltd's reported profit arrived as operating cash — the cash follows the profit. In Mar 26 that was ₹338 Cr of operating cash against ₹327 Cr of profit. After ₹13.0 Cr of capital spending, ₹325 Cr was left as free cash.

Mar 26: operating cash of ₹338 Cr against reported profit of ₹327 Cr, leaving free cash of ₹325 Cr after ₹13.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 96% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

Why conversion sits at 96%: the cash cycle stretched 36 days between Jun 21 and Mar 26 — more of each rupee of profit waits inside the cycle before arriving.

Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Procter & Gamble Health Ltd's cash conversion cycle runs −13 days in Mar 26, up from −49 days in Jun 21. Capital spending ran ₹49.0 Cr over the last 3 years. At Mar 26 sales of ₹1,408 Cr each day of that cycle holds about ₹3.9 Cr, so roughly ₹−50.0 Cr sits inside the business at any moment.

Mar 26: debtors at 43 days, inventory at 137 days — roughly 4.5 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of −13 days, looser than Jun 21's −49.

The full loop: cash goes out to suppliers and production on day 0; stock waits 137 days to sell; customers pay about 43 days after that; and suppliers themselves are paid at 192 days — netting out to the −13-day cycle.

In money terms: at Mar 26 sales of ₹1,408 Cr, each day of the cycle holds about ₹3.9 Cr — so the −13-day loop keeps roughly ₹−50.0 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹49.0 Cr over the last 3 fiscal years against ₹79.0 Cr of depreciation — spending at or below maintenance level. Capital work-in-progress stands at ₹14.0 Cr (Mar 26) — capacity paid for but not yet earning.

The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Procter & Gamble Health Ltd earns a ROCE of 84% in Mar 26. That is up from a trough of 12% in FY14. Return on invested capital clears the cost of that capital by +79.4 percentage points, so growth here adds value rather than only size. The wiring behind it is 23.2% net margin on 1.67× asset turns.

Mar 26 ROCE is 84%, recovered from a FY14 trough of 12% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (Mar 26): 23.2% net margin × 1.67× asset turns × 1.60× balance-sheet leverage ≈ 62.0% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.

The capstone test — ROIC − WACC: 91.4% − 12.0% = a +79.4 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. A spread this wide means every rupee reinvested creates more than a rupee of value — the engine compounds.

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

Procter & Gamble Health Ltd carries total debt of ₹9.0 Cr against shareholder equity of ₹525 Cr as of Mar 26, a debt-to-equity of 0.02 — effectively unlevered. On the annual view that ratio went from 0.00 in FY22 to 0.02 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.

Mar 26: total debt of ₹9.0 Cr against shareholder equity of ₹525 Cr — a debt-to-equity of 0.02. On the annual view, debt-to-equity went from 0.00 (FY22) to 0.02 (FY26). The returns on this page are earned, not borrowed.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Domestic institutions cut 2.1 points of Procter & Gamble Health Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 12.4% of the company. Foreign institutions moved −0.1 points over the same window, to 6.3%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Domestic institutions: −2.1 points over 8 quarters to 12.4%; Foreign institutions: −0.1 points over 8 quarters to 6.3%; Promoters: +0.0 points over 8 quarters to 51.8%.

🚨 Why the register moved: domestic institutions drove it (−2.1 points) — distribution into the market’s bid.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Procter & Gamble Health Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Frequently asked questions